EMAIL THIS PAGE TO A FRIEND

Steroids

Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone.


PMID 18037150

Abstract

The potent antiproliferative effect of progestins has been utilized in clinical regimens for treatment of endometrial proliferative disorders. The progestin infiltrated intrauterine device used as therapy for endometrial carcinoma as well as endometrial hyperplasia yields a hundred-fold increase of local progestin concentration in the endometrium compared to that of oral treatment. The genetic basis for the complex effects of high dose progestins and the different signalling pathways regulated by these genes have never been accurately surveyed. The aim of the present study was to determine the gene expression pattern in highly differentiated endometrial cancer cells (Ishikawa) after short time exposure to high progesterone doses. In eight independent experiments, cells were treated with progesterone (30microg/ml) for 4h and gene expression was compared to that of untreated cells, which served as controls. Microarray analysis revealed 247 differentially expressed genes of which 126 were up-regulated and 121 were down-regulated. Of these, 135 genes are known to be involved in biological processes like cell cycle, cell proliferation and differentiation, developmental processes, immune responses, intracellular protein traffic and transport. Our study shows that microarray analysis can detect relevant gene expression changes in endometrial cells treated with progestin, including those involved in several alternative transcriptional factors and signalling pathways. Many of the differentially expressed genes were not previously known to be affected by progesterone or have unknown biological functions. Characterization of these genes may give new insights into molecular responses to treatment with high progesterone doses. Alternative signalling pathways for progesterone, rather than the classical steroid receptors pathways are also suggested.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

20832-U ORBO 402 Tenax® TA specially treated (35/60), 100/50 mg, W,W,W separators, O.D. × L 8 mm × 100 mm, pkg of 50 ea
20034 ORBO 403 Tenax® TA specially treated (60/80), 100/50 mg, W,W,W separators, O.D. × L 6 mm × 105 mm, pkg of 50 ea
20030-U
ORBO 502 Activated Silica Gel (20/45) 100/50 mg, W,W,F separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea
20032
ORBO 506 Activated Silica Gel (45/60) 300/150 mg, W,W,W separators, O.D. × L 8 mm × 75 mm, pkg of 50 ea
20263
ORBO 52 Large Activated Silica Gel (45/60) 150/150 mg, W,W,W separators, O.D. × L 8 mm × 75 mm, pkg of 50 ea
20229
ORBO 52 Small Activated Silica Gel (20/40) 150/75 mg, pk 50, W,W,F separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea
20265
ORBO 53 Activated Silica Gel (20/40) specially cleaned, 400/200 mg with Glass Fiber Filters, GFF,F,F separators, O.D. × L 7 mm × 100 mm, pkg of 50 ea
20033
ORBO 554 H2SO4 on Silica Gel (20/40) 150/75 mg, W,W,W separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea
20049 ORBO 605 Amberlite® XAD®-2 specially cleaned (20/50) 100/50 mg, W,W,W separators, O.D. × L 6 mm × 100 mm, pkg of 50 ea
20050-U ORBO 608 Amberlite® XAD®-2 (20/50) 150/75 mg, W,W,W separators, O.D. × L 8 mm × 110 mm, pkg of 50 ea
20051 ORBO 609 Amberlite® XAD®-2 (20/50) 400/200 mg, W,W,W separators, O.D. × L 8 mm × 110 mm, pkg of 50 ea
20052 ORBO 613 Amberlite® XAD®-4 80/40 mg, W,W,W separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea
20029-U ORBO 65P (OVS) Amberlite® XAD®-4 specially cleaned, 160/80 mg, RC,GFF,F,F (specially cleaned) separators, O.D. × L 13-8 mm × 75 mm , OSHA Versatile Sampler (OVS), pkg of 10 ea
20812-U ORBO 80 Coated Filter, with cassettes (unassembled)
20811
ORBO 80 Isocyanate Filter, with cassettes: no, filter O.D. 37 mm, pkg of 25 ea
20069
ORBO 827 LpDNPH Coated Filter, 37mm, pkg of 25 ea
20362 ORBO 92 Carboxen® 564 (20/45), 160/80 mg, W,F,F separators, O.D. × L 6 mm × 75 mm, pkg of 25 ea, for analyte group Vinyl acetate